# The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

> **NCT02098395** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 835 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** liraglutide
- **DRUG:** liraglutide
- **DRUG:** liraglutide
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02098395
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 835 (ACTUAL)
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02098395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02098395, "The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02098395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*